| Literature DB >> 25010007 |
Zhi-Ping Tan1, Li Xie2, Yao Deng2, Jin-Lan Chen2, Wei-Zhi Zhang2, Jian Wang1, Jin-Fu Yang1, Yi-Feng Yang1.
Abstract
SCN5A mutations have been reported to underlie a variety of inherited arrhythmias, while the complex overlapping phenotype, especially with congenital heart disease (CHD), is rarely reported. The 48-year-old proband underwent a recent syncope during rest. A CHD (tetralogy of Fallot) and conduction disease was revealed by echocardiogram and ultrasonic cardiogram examination. We combined whole-exome sequencing (WES) and bioinformatics strategies to identify the pathogenic gene for this autosomal-dominant cardiac conduction disease (CCD) in a multi-generation pedigree. We examined four members of this family, including three affected and one unaffected. A novel nonsense mutation (Y1495X) in SCN5A was identified in the affected family members. This mutation is predicted to generate a truncated SCN5A protein, which could result in the loss of sodium current, a defined mechanism of SCN5A related arrhythmias. Our study provides evidence that WES is a highly effective approach for genetic analyses of rare clinical phenotypes. Our study also offers accurate genetic testing information for those yet clinically negative relatives.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25010007 PMCID: PMC5375973 DOI: 10.1038/srep05616
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Clinical features of family members with conduction diseases.
(A) Electrocardiograms (ECGs) of the family members (II-3, III-8, IV-1, IV-4) and the proband (III-10). (B) Ultrasonic cardiogram (UCG) of proband shows cardiac structural defect, tetralogy of Fallot (TOF). (C) Computed tomography (CT) of the proband's heart shows a pulmonary hypoplasia.
Demographic and electrocardiographic features in members of the family
| ECG intervals (ms) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Member | Sex | Age (Years) | Symptoms | Clinical ECG Diagnosisi | QRS Axis | Heart Rate (Beats/min) | PR | QRS | QT/QTc | others | Mutation (Y1495X) |
| II-1 | M | 76 | Asymptomatic | no | −2 | 83 | 190(210) | 82(100) | 368/432 | - | |
| II-3 | M | 72 | Syncope(>20) | Sinus bradycardia, LAFB, T wave abnormalities | −67 | 446/418 | + | ||||
| II-5 | F | 35 | Syncope | NA | NA | NA | NA | NA | NA | Sudden death | NA |
| II-7 | M | 37 | Syncope | NA | NA | NA | NA | NA | NA | Sudden death | NA |
| II-8 | F | 64 | Syncope(>10) | RBBB | −65 | 438/426 | + | ||||
| III-6 | M | 39 | 3syncopes | RBBB | 61 | 208(210) | 430/432 | + | |||
| III-8 | M | 35 | 3 syncopes | RBBB | 268 | 74 | 168(210) | 422/468 | + | ||
| III-10 | M | 48 | 3 syncopes | Sinus bradycardia, first degree AVB | 254 | 446/434 | CHD (TOF) | + | |||
| III-14 | F | 46 | Asymptomatic | no | 42 | 82 | 138(210) | 80(90) | 370/432 | − | |
| III-18 | M | 30 | 2 syncopes | RBBB | 14 | 56 | 204(210) | 434/434 | + | ||
| IV-1 | M | 8 | 1 syncope | LAFB | −41 | 75 | 148(170) | 382/426 | + | ||
| IV-2 | F | 5 | Asymptomatic | no | 42 | 124 | 128(170) | 62(90) | 306/439 | − | |
| IV-4 | M | 18 | 2 syncopes | Sinus bradycardia | 74 | 96(100) | 454/383 | + | |||
NA = not available; QTc = corrected QT interval; RBBB = Right Bundle Branch Block; LAFB = Left anterior fascicular block. AVB = atrioventricular Block; CHD = congenital heart disease; TOF = tetralogy of Fallot.
+ Y1495X present, − Y1495X absent.
*Whole- exome sequenced.
†Age of death.
#Index case.
Figure 2Whole exome sequencing and familial genomic tetra-overlapping for the identification of a novel genetic variant for multiple complex syndromes.
(A) Pedigree of the family. Black circles/squares are affected, white are unaffected. Arrow indicates the proband. 4 large circles (3 in red and 1 in blue) represent the 4 individuals underwent whole exome sequencing. Plus signs indicate Y1495 SCN5A mutation positive. Minus signs indicate mutation-negative. NA represents DNA samples were not available. (B) Overlapping filter strategy. Asterisks denotes remaining variants for further analysis that are present in 3 affected members (red circles) but not in the normal control (blue circle). (C) Sanger DNA sequencing chromatogram demonstrates the heterozygosity for a SCN5A mutation (p.Y1495X, c.4485C > A). (D) Schematic representation of the filter strategies employed in our study.
Summary of SNPs for exome captured samples and filter procedure
| Categories | III-10 | II-3 | IV-1 | III-14 (control) |
|---|---|---|---|---|
| Target region (bp) | 62085286 | 61988644 | 62085286 | 62085286 |
| Raw reads | 92737976 | 138497858 | 145426084 | 139851618 |
| Raw data yield (Mb) | 9465 | 11149 | 11707 | 11258 |
| Reads mapped to genome | 93894979 | 140334153 | 147846058 | 142256214 |
| Reads mapped to target region | 53479844 | 82582631 | 87924642 | 82990685 |
| Data mapped to target region (Mb) | 3677.14 | 5658.73 | 6019.33 | 5690.76 |
| Coverage of target region (%) | 95.68 | 95.93 | 95.69 | 95.84 |
| Average read length (bp) | 80.5 | 80.5 | 80.51 | 80.5 |
| Fraction of target covered > = 10X (%) | 93.27 | 94.02 | 93.93 | 93.96 |
| Fraction of target covered > = 20X (%) | 89.6 | 91.86 | 91.83 | 91.76 |
| Fraction of target covered > = 30X (%) | 81.92 | 88.12 | 88.16 | 87.88 |
| No. high-confidence genotypes | 115744429 | 115676179 | 113537889 | 114980456 |
| Total number of SNPs | 85738 | 91309 | 89061 | 89972 |
| Missense | 11032 | 11352 | 11127 | 11269 |
| Nonsense | 127 | 144 | 143 | 143 |
| Splice site | 2498 | 2675 | 2651 | 2682 |
| Synonymous-coding | 9600 | 9934 | 9792 | 9894 |
| Hom | 36615 | 37234 | 37483 | 37668 |
| Het | 49123 | 54075 | 51578 | 52304 |
| Novel variants | ||||
| Number not in dbSNP | 1287 | 1373 | 1358 | 1241 |
| Number not in 1000 Genome and YH | 765 | 787 | 779 | 755 |
| Missense | 624 | 631 | 632 | 610 |
| Nonsense | 15 | 21 | 23 | 19 |
| Splice site | 126 | 135 | 124 | 126 |
| No. of genes presented in 3 affected patients but not in the normal family member III-14 | 32 | |||
| Top-ranked detrimental effect of variants by three distinct programs (Polyphen2, SIFT and MutationTaster) | 15 | |||
| No. of validated variants co-segregating with affected members | 1 | |||
*Index patient.
(1)Target regions refer to the regions that are actually covered by the designed probes.
(2)Reads mapped to target regions are reads that within or overlap with target region.
(3)Intronic SNPs within 10 bp of exon/intron boundary.